Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2025)

Legend Biotech (LEGN) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $2.1 million in Q3 2025.

• In Q3 2025, Depreciation & Amortization (CF) fell 9.87% year-over-year to $2.1 million; the TTM figure through Dec 2025 stood at $6.7 million (down 37.26% YoY), while the FY2024 annual figure was $10.7 million, changed 0.04% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.1 million in Q3 2025, from $2.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.2 million in Q1 2022 and bottomed at -$20000.0 in Q4 2021.
• A 5-year average of $2.4 million and a median of $2.7 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 12505.0% in 2022, down 38.93% in 2022.
• Year by year, Depreciation & Amortization (CF) stood at -$20000.0 in 2021, then jumped by 12505.0% to $2.5 million in 2022, then advanced by 9.88% to $2.7 million in 2023, then grew by 0.62% to $2.7 million in 2024, then fell by 21.76% to $2.1 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $2.1 million (Q3 2025), $2.3 million (Q2 2025), and $2.3 million (Q1 2025), per Business Quant data.

Peer Comparison